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Abstract 
Review on STAT2, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
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Identity 
HGNC (Hugo): STAT2 
Location: 12q13.3 
DNA/RNA 
Description 
24 exons spanning 18657 bp 
Transcription 
There are two major transcripts. In transcript variant 
1, mRNA is 4576 bp. Transcript variant 2 uses an 
alternate in-frame splice site in exon 3; as a result, it 
lacks an internal 12bp insertion compared to 
transcript variant 1. Another spliced form is 
generated by reading through the intron between 
exons 20 and 21, which correspond to the region 
encoding the SH2 domain. The spliced form contains 
a stop codon in the SH2 domain, giving rise to a short 
form of STAT2 when the mRNAs are translated. The 
putative translated proteins lack half of the SH2 
domain, the tyrosine phosphorylation site required 
for dimerization and DNA binding, and the C-
terminal activation domain. 
Protein 
Description 
There are two major isoforms of STAT2.  
The long form is known as isoform 1 and is a 851 
amino acid protein (113KDa on gels).  
Isoform 2 lacks an internal four amino acid segment 
compared to isoform 1. 
The STAT2 gene product contains 6 domains: an N-
terminal domain (NTD), a coiled-coil domain (CC), 
a DNA-binding domain (DBD), a linker domain 
(LD), a Src homology-2 domain (SH2), and a 
transactivation domain (TAD) (figure 1).  
NTD is required for tyrosine phosphorylation of 
STAT2 in response to type I IFNs, binding of 
STAT2 to IFN receptors and cooperative binding of 
STAT1:STAT2 heterodimers or ISGF3 to promoters 
that contain tandem GAS or ISRE, respectively.  
CC mediates protein interactions and is the domain 
IRF9 binds. DBD does not bind DNA as a part of 
ISGF3. DBD contains a bipartite nuclear localization 
signal (NLS) when ISGF3 forms. No function for 
LD is known. SH2 serves 2 main functions: binding 
to a phosphorylated IFN receptor, thereby making 
STAT2 available for Tyk2-mediated tyrosine 
phosphorylation; and binding to tyrosine 
phosphorylated STAT1 to form an active 
heterodimer.  
The TAD is essential for recruitment of transcription 
regulators. TAD also contains the nuclear export 
signal (NES).  
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Nucleocytoplasmic shuttling of STAT2 is attributed 
to the constitutive binding of STAT2 to the NLS-
containing IRF9 to transport STAT2 into the 
nucleus, while the STAT2 NES exports STAT2 back 
to the cytosol (Steen and Gamero, 2012). 
Interferons (IFNs) activate the Janus kinase 
(JAK)/STAT pathway by binding to their 
corresponding receptor complex. Jak1 and TYK2 are 
pre-associated with type I and type III IFN receptors, 
and phosphorylate specific tyrosine residues within 
the receptor chain, which serve as docking sites for 
the recruitment of STATs. JAKs phosphorylate a 
conserved tyrosine residue situated in the C-terminal 
region of STAT2 (Y690) and STAT1 , thus allowing 
STAT1 and STAT2 to interact via reciprocal SH2-
phosphotyrosyl interactions. Formation of the 
interferon-stimulated gene factor 3 (ISGF3) complex 
takes place when activated STAT1:STAT2 
heterodimers are released from receptor chains to 
bind the DNA-binding adaptor protein, IRF9 
(p48/ISGF3G). ISGF3 translocates to the nucleus 
and binds the DNA containing an IFN-stimulated 
response element (ISRE) by STAT1 and IRF9 to 
activate gene transcription of IFN-stimulated genes 
(ISGs). In addition, STAT2 can form heterodimers 
individually with either STAT1 or IRF9. Each of 
these complexes will bind IRSE or IFN-gamma 
activation sequences (GAS) to activate gene 
transcription of ISGs. Serine 287 phosphorylation 
can negatively regulate the biological activities of 
type I IFNs (Steen et al., 2013). IFNs are the only 
cytokines known to date that can activate STAT2. 
Expression 
STAT2 is ubiquitously expressed in most cell types. 
Localisation 
STAT2 predominantly resides in the cytoplasm. 
Nucleocytoplasmic shuttling occurs in the absence 
of IFN stimulation, but translocates to the nucleus 
upon tyrosine phosphorylation when stimulated by 
IFNs (Reich, 2013). 
Function 
Transcription factor. STAT2 mediates the 
transcription of numerous IFN-induced genes 
involved in linking adaptive and innate immunity 
and exerting antiviral, antiproliferative, apoptotic, 
and antitumor effects. 
Homology 
Shares homology with the other 6 mammalian STAT 
genes: STAT1, STAT3, STAT4, STAT5A, 
STAT5B, STAT6. Human STAT2 is relatively well 
conserved with macaque and chimpanzee. Human 
and murine STAT2 are highly homologous (76% 
identity over the first 712 amino acids). 
Mutations 
Note 
Two mutations in intron 4 (Hambleton,et al., 2013) 
as well as the intron between exon 20 and 21 were 
found to prevent correct splicing of STAT2 
(Sugiyama et al., 1996). 
Implicated in 
The antigrowth and immunomodulatory actions of 
interferons (IFNs) have enabled these cytokines to 
be used therapeutically for the treatment of a variety 
of hematologic and solid malignancies. The loss of 
IFN sensitivity may contribute to the development 
and progression of cancers. STAT2 is found to be 
decreased in many cancers including squamous cell 
carcinoma of the skin (Clifford et al., 2000; Clifford 
et al., 2002), fibrosarcoma (Krishnamurthy et al., 
2006), astrocytomas (Ehrmann et al., 2008), 
melanoma (Mischiat et al., 2006), and prostate 
cancer (Ni et al., 2002). STAT2 has a tumor 
suppressor function (Clifford et al., 2002; Gamero et 
al., 2010; Yue et al., 2015) , though the mutations 
have not yet been identified in human cancer.  
To evade the antiviral protective effects of IFNs, 
certain viruses have developed strategies to impair 
the IFN signaling pathway by specifically targeting 
STAT2. The strategies are to reduce STAT2 levels, 
to sequester STAT2 in the cytoplasm, or to prevent 
its tyrosine phosphorylation. 
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